Your browser is no longer supported. Please, upgrade your browser.
Brainstorm Cell Therapeutics Inc.
Index- P/E- EPS (ttm)-1.04 Insider Own0.10% Shs Outstand33.31M Perf Week-5.23%
Market Cap139.37M Forward P/E- EPS next Y-0.92 Insider Trans0.00% Shs Float29.22M Perf Month-33.94%
Income-31.80M PEG- EPS next Q-0.26 Inst Own23.10% Short Float14.45% Perf Quarter-24.00%
Sales- P/S- EPS this Y-0.40% Inst Trans19.70% Short Ratio3.66 Perf Half Y-68.11%
Book/sh1.06 P/B3.76 EPS next Y33.30% ROA-105.00% Target Price- Perf Year-42.26%
Cash/sh1.20 P/C3.33 EPS next 5Y- ROE-158.50% 52W Range3.80 - 17.95 Perf YTD-11.82%
Dividend- P/FCF- EPS past 5Y-18.20% ROI- 52W High-77.77% Beta0.14
Dividend %- Quick Ratio3.80 Sales past 5Y- Gross Margin- 52W Low5.00% ATR0.61
Employees40 Current Ratio3.80 Sales Q/Q- Oper. Margin- RSI (14)33.34 Volatility6.70% 9.04%
OptionableYes Debt/Eq0.00 EPS Q/Q-4.90% Profit Margin- Rel Volume0.46 Prev Close4.15
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume1.16M Price3.99
Recom3.00 SMA20-34.46% SMA50-27.65% SMA200-59.18% Volume544,498 Change-3.86%
Feb-04-21Upgrade Maxim Group Hold → Buy $12
Nov-17-20Downgrade Maxim Group Buy → Hold
Dec-19-16Reiterated Maxim Group Buy $5 → $6
Dec-22-15Reiterated Maxim Group Buy $14 → $5
Mar-03-21 03:49AM  
Feb-26-21 11:00AM  
Feb-24-21 03:51PM  
Feb-23-21 08:00AM  
Feb-22-21 03:49PM  
Feb-09-21 09:00AM  
Feb-06-21 01:30AM  
Feb-05-21 07:45AM  
Feb-04-21 06:31PM  
Jan-28-21 08:30AM  
Jan-25-21 06:10AM  
Jan-20-21 09:08AM  
Dec-28-20 07:00AM  
Dec-18-20 07:00AM  
Dec-14-20 07:00AM  
Dec-08-20 12:23AM  
Nov-26-20 11:36PM  
Nov-23-20 07:00AM  
Nov-19-20 07:11AM  
Nov-17-20 12:31PM  
Oct-26-20 06:00AM  
Oct-23-20 05:30AM  
Oct-22-20 09:00AM  
Oct-19-20 07:57AM  
Oct-16-20 06:00AM  
Oct-15-20 07:00AM  
Oct-12-20 06:00AM  
Oct-09-20 06:51AM  
Oct-02-20 01:00AM  
Sep-30-20 05:00AM  
Sep-29-20 06:00AM  
Sep-16-20 07:30AM  
Sep-03-20 09:00AM  
Sep-02-20 08:30AM  
Aug-25-20 07:39AM  
Aug-19-20 08:13AM  
Aug-10-20 09:03AM  
Aug-07-20 05:50AM  
Aug-05-20 07:00AM  
Jul-27-20 07:58AM  
Jul-23-20 04:36PM  
Jul-09-20 09:10AM  
Jul-08-20 05:31AM  
Jul-02-20 06:49AM  
Jul-01-20 08:50AM  
Jun-25-20 08:26AM  
Jun-24-20 09:06AM  
Jun-23-20 05:45AM  
Jun-15-20 09:00AM  
Jun-11-20 07:28AM  
Jun-10-20 05:40AM  
Jun-09-20 06:00AM  
Jun-04-20 07:09PM  
Jun-03-20 06:00AM  
Jun-02-20 06:00AM  
May-27-20 07:25AM  
May-18-20 06:06AM  
May-08-20 05:35AM  
May-07-20 06:30AM  
May-04-20 03:30AM  
Apr-29-20 06:00AM  
Apr-08-20 06:40AM  
Apr-03-20 06:59AM  
Apr-01-20 09:00AM  
Mar-31-20 04:00AM  
Mar-16-20 03:00AM  
Mar-06-20 09:25AM  
Feb-27-20 01:00AM  
Feb-20-20 05:10AM  
Feb-18-20 07:00AM  
Feb-17-20 01:00AM  
Feb-11-20 06:00AM  
Feb-10-20 01:00AM  
Feb-04-20 04:45AM  
Jan-29-20 04:00AM  
Jan-21-20 09:53AM  
Jan-17-20 06:00AM  
Jan-07-20 01:00AM  
Jan-03-20 10:21AM  
Dec-19-19 05:00AM  
Dec-18-19 05:00AM  
Dec-11-19 05:00AM  
Nov-26-19 08:05AM  
Nov-25-19 06:00AM  
Nov-21-19 06:15AM  
Nov-20-19 07:00AM  
Nov-18-19 06:32AM  
Nov-14-19 08:07AM  
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; and in Phase II for the treatment of progressive multiple sclerosis and alzheimer's disease, as well as for other central nervous system disorders. The company has a partnership with Catalent for the manufacture of NurOwn. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Setboun DavidEVP and COOJul 16Buy12.955,00064,74055,000Jul 16 05:10 PM
ACC International Holdings LtdMember of 10% owner groupJul 16Sale13.477,823105,35167,053Jul 16 05:05 PM
Abbhi SankeshDirectorJul 15Buy12.9946,779607,6592,164,530Jul 16 05:15 PM
ACC International Holdings LtdMember of 10% owner groupJul 15Sale13.1218,430241,71574,876Jul 16 05:05 PM
ACC International Holdings LtdMember of 10% owner groupJul 13Sale13.5240,000540,95293,306Jul 16 05:05 PM
ACC International Holdings LtdMember of 10% owner groupJul 10Sale13.352,00026,700133,306Jul 16 05:05 PM
ACC International Holdings LtdMember of 10% owner groupJul 09Sale13.133,50045,939135,306Jul 16 05:05 PM